Tempus AI, Inc. (TEM)

NMS – Real vaqt narxi. Valyuta: USD

56.14

+1.27 (2.31%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

55.99

-0.15 (-0.27%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

16.06.2026

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.

11.06.2026

Tempus AI: AI Precision Medicine With A Moat

Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data inaccessible to generic AI models. With a market cap under $9B and trading at ~4.5x forward sales, the stock's valuation is compelling given management's 25% annual growth target versus more conservative analyst estimates.

11.06.2026

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl.

09.06.2026

Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy

Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust at ~25% for 2026, with no adverse revisions for 2027–2028, and margin mix shifting toward higher-margin Data and Applications segments. Adjusted operating loss has narrowed significantly, and TEM is approaching operating breakeven, supporting the SaaS-like trajectory critical for long-term value.

09.06.2026

Tempus AI: A Unique AI Business Model With Asymmetric Upside

Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships. Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry.

09.06.2026

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry's ExomeReveal workflow; an in.

08.06.2026

Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Videolar

08.08.2025

Positive

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
TEM	BTIG Research	Buy	undefined >> $60	April 21st 2025
TEM	JP Morgan	Neutral	$50 >> $55	February 25th 2025
TEM	William Blair	Market Perform	undefined >> undefined	February 12th 2025

Press-relizlar

11.06.2026

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

09.06.2026

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

03.06.2026

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium (“IMS Consortium”). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to devel.

01.06.2026

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025.

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

Tempus AI: AI Precision Medicine With A Moat

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy

Tempus AI: A Unique AI Business Model With Asymmetric Upside

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing